


U. S. Patent and Trademark Office
Board of Appeal and Interferences
Fax No.: + 571-273-8300

0053

My Reference: Patent Application Number: 09/944,564

Date: October 16, 2006
Total number of pages: 3



Fax letter

Credit Card Payment Form

Notice of Appeal From the Examiner to the Board of Appeal and Interferences
Submitted in
Response to Office Action dated 07/11/2006 (Final Rejection)

Dear Sir:

In relation to the above-identified patent application, a notice of appeal have been filed on the October 10, 2006. Please find payment for this appeal by credit card.

Best regards

A handwritten signature in black ink, appearing to read "N. Nasif", with a long horizontal flourish underneath.

The Inventor
Nida Nasif



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/944,564	09/04/2001	1623	1259			24	15

CONFIRMATION NO. 8476

UPDATED FILING RECEIPT



OC000000007223833

AL-JASSIM, Rawaa
2578 River Woods Drive
Naperville, IL 60565

Date Mailed: 12/21/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Nida Abdul-Ghani Nassief, Doha, IRAQ;

Domestic Priority data as claimed by applicant

Foreign Applications

UNITED KINGDOM 9904777.1 03/02/1999

If Required, Foreign Filing License Granted 10/06/2001

Projected Publication Date: 03/28/2002

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Asthma/allergy therapy that targets T-lymphocytes and/or eosinophils

Preliminary Class

514

3

Original Copy
of Fax letter
+
Reference

U. S. Patent and Trademark Office
Board of Appeal and Interferences
Fax No.: + 571-273-8389 0053

My Reference: Patent Application Number: 09/944,564



resend :
correction of time & date
for proper record
Fax letter

Date: October 10, 2006
Total number of pages: 10
Annexes will be sent by mail

Notice of Appeal From the Examiner to the Board of Appeal and Interferences
Submitted in
Response to Office Action dated 07/11/2006 (Final Rejection)

Dear Sir:

In response to the above-identified final rejection of my patent application claims 25-27, may I kindly submit the following response:

- 1- By submitting a Notice of Appeal From the Examiner to the Board of Appeal and Interferences [Form: PTO/SB/31 (07-06)].
- 2- Payment by Credit Card. Form PTO-2038 is attached.
- 3- Objection to the Examiner decision by submitting further evidence from medical textbooks clarifying the point of dispute with the examiner; in relation to the definition of asthma and asthmatic bronchitis, and differentiating them as unrelated separate medical entities, thus rendering my claims in the use of glycoposphopeptical in the treatment of asthma patentable and valid.
- 4- Amendment of claim 25, currently reads as "25. (New) A pharmaceutical composition consisting essentially of glycoposphopeptical for oral administration for the treatment of allergy and asthma in dosage and duration which is effective to....etc"; may I kindly request separation of the use of glycoposphopeptical in the treatment of allergy from its use in the treatment of asthma. Discussion of the use in the treatment of allergy are part of the response to Office Action dated

Detailed response will follow.

Thank you for considering my appeal.

Best regards

The Inventor
Nida Nasif



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.USPTO.GOV

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/944,564	09/04/2001	1623	0.00			24	15

CONFIRMATION NO. 8476

FILING RECEIPT



OC000000006875011

AL-JASSIM Rawaa
24 W. 601 Birdsong Court
Naperville, IL 60540

Date Mailed: 10/09/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Nida Abdul-Ghani Nassief, Doha, IRAQ;

Domestic Priority data as claimed by applicant

Foreign Applications

UNITED KINGDOM 9904777.1 03/02/1999

If Required, Foreign Filing License Granted 10/06/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Asthma/allergy therapy that targets T-lymphocytes and/or eosinophils

Preliminary Class

514